StocksDeepDive
Snapshot · Russell 3000 · generated 2026-11-11 21:49 UTC

ORMP — Oramed Pharmaceuticals Inc.

EXPENSIVE (MOS Model unreliable) · Quality 96/100

Value Score 30 days ago: 31.1 → today 32

Price
4.13
Intrinsic value
1.16
Margin of safety
Model unreliable
Implied growth (reverse DCF)
+33.4%
model assumes +10.0%
Value Score
32
Quality
96
Psychology
22.7
Discovery
6.1
price/volume attention only
Moat score
26.7
erosion: none

Value Score: top 36% of Russell 3000 · Quality: top 1%

Dividend: 0.25/share (TTM) · yield 6.0% · payout 6%

Open the interactive Deep Dive for ORMP →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/ORMP - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is ORMP undervalued?

As of 2026-11-11, ORMP trades at 4.13 against a computed intrinsic value of 1.16 (-256.0% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is Oramed Pharmaceuticals Inc.'s Value Score?

Oramed Pharmaceuticals Inc.'s Value Score is 32 as of 2026-11-11 - it combines value, quality, crowd psychology and market attention into one number.

Does ORMP pay a dividend?

Yes - ORMP's trailing twelve-month dividend is 0.25/share, a yield of 6.0% at the current price (as of 2026-11-11).